Verseon to Present Latest Anticoagulant Results at Bio 2016
Fremont, Calif. - Verseon Corporation's (AIM: VSN) Dr. David Kita, Vice President of Research and Development, will present the latest data on Verseon's new class of anticoagulants at the 2016 BIO international Convention in San Francisco on Tuesday, 7 June. Dr. Kita's presentation will include the latest data on pharmacological safety assessment and the establishment of dose response in preclinical efficacy models. This new collection of data will form an important part of Verseon's upcoming Investigational New Drug (IND) application for this program.
About Verseon’s Anticoagulant Program
Verseon's new class of anticoagulants are part of a growing portfolio of drug programs being developed with the aid of its proprietary, computational drug discovery platform. The novel small-molecule direct thrombin inhibitors (DTIs) act through reversible covalent inhibition. This unique mode of action that leads to novel pharmacology, including lower bleeding liability as seen in multiple preclinical tests. In addition to efficacy and lower bleeding risk, Verseon's new class of anticoagulants also has pharmacokinetic properties suitable for oral dosing.
Verseon is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today's challenging diseases. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.
Note to Editors
Dr. David Kita will be available for interviews at the BIO international Convention in San Francisco to discuss this new collection of data.
For further information please contact
|Verseon Corporation||+1 (510) 225 9000|
|Arthur Shmurun / Amy Thai|
Financial and business media enquiries:
|Abchurch Communications Limited||+44 (0) 20 7398 7719|
|Jamie Hooper / Alex Shaw|
Trade and pharma media enquiries:
|Vane Percy Roberts||+44 (0) 1737 821 890|
|Simon Vane Percy|